Peptide Decoding

What changed

Latest price capture: Oct 24, 2026.

Price moves since the last capture

Between Oct 22, 2026 and Oct 24, 2026, 6 of 105 tracked compound sizes moved more than 5%.

Market median per mg at each compound's most-listed vial size, where both captures had at least 3 stores.

Largest decreases

  1. Eloralintide10 mg$16.80/mg → $15.90/mg -5.4%
  2. CJC-1295 (no DAC) + GHRP-2 blend10 mg$7.90/mg → $7.50/mg -5.1%
  3. P2110 mg$11.90/mg → $11.45/mg -3.8%
  4. IGF-1 LR31 mg$74.90/mg → $73.50/mg -1.9%
  5. AHK-Cu100 mg$0.63/mg → $0.62/mg -1.6%
  6. B7-336 mg$10.33/mg → $10.16/mg -1.6%
  7. Tirzepatide10 mg$7.32/mg → $7.20/mg -1.6%

Largest increases

  1. N-Acetyl Selank10 mg$5.50/mg → $6.50/mg +18.2%
  2. FOXO4-DRI10 mg$14.65/mg → $16.75/mg +14.3%
  3. Humanin10 mg$12.15/mg → $13.03/mg +7.2%
  4. Triptorelin2 mg$19.25/mg → $20.50/mg +6.5%
  5. LL-375 mg$11.30/mg → $11.80/mg +4.4%
  6. Sermorelin + Ipamorelin blend10 mg$7.40/mg → $7.70/mg +4.1%
  7. Vesilute20 mg$3.10/mg → $3.20/mg +3.2%
  8. CagriSema10 mg$9.00/mg → $9.25/mg +2.8%
  9. Kisspeptin10 mg$5.35/mg → $5.50/mg +2.8%
  10. Tesamorelin + Ipamorelin blend13 mg$7.50/mg → $7.69/mg +2.5%

New compound pages

  • Acetyl Tetrapeptide-9Oct 24, 2026

    The in-vitro numbers are specific and the human evidence is one uncontrolled study the supplier ran.

  • BI 3034701Oct 24, 2026

    The drug that shows 'triple agonist' is a shape, not a mechanism.

  • CarperitideOct 24, 2026

    The A in the natriuretic alphabet, and the only one of the three routinely given to patients anywhere. The evidence behind that use is thinner than its 30 years on the market suggest.

  • CenderitideOct 24, 2026

    A designed chimera rather than a copy of anything the body makes. The engineering is the interesting part.

  • NeurotensinOct 24, 2026

    One of the foundational neuropeptides. Decades of biology, no approved use.

  • Pentagastrin (Peptavlon)Oct 24, 2026

    A diagnostic rather than a treatment: the point was to provoke the stomach, measure it, and go home.

  • UlaritideOct 24, 2026

    The clearest demonstration on this site that moving the numbers is not the same as helping the patient.

  • Vancomycin (Vancocin)Oct 24, 2026

    The clearest case on this site of something called a peptide that is not one in the sense readers here mean.

  • AprotininOct 23, 2026

    The clearest case on this site of a regulator reversing itself: suspended on one trial, restored when that trial was re-examined.

  • ASC37Oct 23, 2026

    A 41-amino-acid GLP-1, GIP and glucagon peptide with no human data of any kind, and company press releases as its entire evidence base.

  • CB4211Oct 23, 2026

    A modified MOTS-c analog that completed human safety trials and was abandoned over its formulation.

  • CertepetideOct 23, 2026

    It does not attack the tumor. It binds integrins to trigger a transport pathway that carries other drugs inside.

  • MENTSHOct 23, 2026

    A 2026 discovery from the lab that found MOTS-c and the SHLP peptides. Mouse and genetics work only, and nobody sells it.

  • PL8177Oct 23, 2026

    A melanocortin peptide built around the same core as PT-141, aimed at the gut wall instead of the brain.

  • PL9643Oct 23, 2026

    An investigational eye drop whose phase 2 missed both primaries outright, whose phase 3 result depends on which analysis you read, and which its developer has now licensed out.

136 compound pages were added in the last 30 days.

New guides and news

61 guides and news pages were added in the last 30 days.

Captures

  • Oct 24, 2026259 compound sizes with 3+ stores
  • Oct 22, 2026252 compound sizes with 3+ stores
  • Oct 21, 2026252 compound sizes with 3+ stores
  • Oct 20, 2026246 compound sizes with 3+ stores
  • Oct 19, 2026230 compound sizes with 3+ stores